Navigation Links
ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders
Date:9/6/2010

ead to macular hole, where the traction from the vitreomacular adhesion actually pulls off a piece of the macula (the part of the retina responsible for central vision). If not treated with major eye surgery called a vitrectomy, which involves using suction to remove the vitreous from the eye, macular hole can lead to irreversible, central blindness. While vitrectomy is generally effective in closing macular holes, it is an invasive procedure and a proportion of patients experience side-effects. These include alteration of vision, bleeding, retinal detachment and development of glaucoma and cataracts. Therefore, a nonsurgical treatment option for such patients could be an important breakthrough in the way macular hole patients are treated.

The MIVI-TRUST Program

The microplasmin Phase III program, referred to as MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment), consists of two multi-center, randomized, placebo controlled, double-masked trials. These trials are designed to evaluate a single dose of 125μg microplasmin versus placebo in the intravitreal treatment of patients with symptomatic focal vitreomacular adhesion (VMA). The primary endpoint of both trials is the non-surgical resolution of focal vitreomacular adhesion one month after a single injection of microplasmin. This endpoint is assessed using optical coherence tomography (OCT). The MIVI-TRUST program is the largest interventional clinical program ever performed to specifically evaluate the vitreoretinal interface in patients with retinal disorders. In total, over 650 patients were enrolled in these trials, which were held across 90 centers in 7 countries.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin has completed two P
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
11. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 CytRx Corporation ... development company specializing in oncology, today announced that ... Executive Officer, and David Haen , Vice ... present a corporate overview at two significant investment ... and healthcare industries: the FBR & Co. Second ...
(Date:9/1/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... development and sale of broadly enabling, pressure cycling ... life sciences industry, today announced the publication of ... PCT Platform could play a significant role in ... is based on PCT,s unique ability to help ...
(Date:9/1/2015)... BerGenBio AS ("BerGenBio" or the ... has appointed Hilde Furberg and Dr ... of Directors, effective immediately. Hilde Furberg ... and biotech and is currently Senior Vice President Rare ... role was Vice President and General Manager of Nordic ...
Breaking Medicine Technology:CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5BerGenBio Appoints Non-Executive Directors 2
(Date:9/1/2015)... ... September 01, 2015 , ... Agriculture innovation, urban farming, local ... the topics to be discussed at Seedstock’s 4th Annual Sustainable Agriculture Conference : ... San Diego. , In addition to keynotes Pierre Sleiman, founder and CEO of ...
(Date:9/1/2015)... Switzerland (PRWEB) , ... September 01, 2015 , ... ... “Calibration and Qualification of Laboratory Instruments in accordance with GMP requirements“ , featuring ... presented on October 6th, 2015 at 11:00 EDT (15:00 GMT). , Calibration, ...
(Date:9/1/2015)... NY (PRWEB) , ... September 01, 2015 , ... ... as the 2015-2016 Distinguished Nurse Scholar-in Residence at the Institute of Medicine (IOM) ... Professor of Biomedical Informatics at Columbia University School of Nursing. A member of ...
(Date:9/1/2015)... ... September 01, 2015 , ... CanAm Enterprises LLC, ... received permanent green cards (I-829 petition approval) from the USCIS through an investment ... final step of the EB-5 visa process for immigrant investors to become lawful ...
(Date:9/1/2015)... ... September 01, 2015 , ... The PracticeMatch Career ... pm at the Marriott Indianapolis Downtown, 350 West Maryland Street, Indianapolis, IN 46225. ... from across the country. All specialties will be represented. Attendees will enjoy free ...
Breaking Medicine News(10 mins):Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4
... larger tumors , , THURSDAY, March 19 (HealthDay News) -- ... tumor improves tumor-free survival, a U.S. study has confirmed. ... cancer of the intestinal tract, typically occur in the ... are diagnosed in the United States each year. According ...
... Pharmaceuticals (NYSE: VRX ) today announced that ... of President, Valeant Pharmaceuticals International, effective March 10, 2009. ... for overseeing the Dow Services business, corporate business development ... and will be a member of Valeant,s Executive Management ...
... Abaxis, Inc. (Nasdaq: ABAX ), a ... today that Don Wood, vice president of operations, will ... on Thursday, March 26, 2009. The conference is a ... be held at the Cliff Lodge Snowbird Ski Resort ...
... Based on its recent analysis of the medical ... with the 2009 North American Frost & Sullivan ... The honor serves as recognition of the growth ... upon since the firm,s acquisition of Dynamic Imaging ...
... Anesthesiologists, Action vs. RhetoricCORONA DEL MAR, Calif., March 19 ... fair odds. Yet, that,s exactly what the foremost international ... the stage for last week when he responded to ... release in which they claimed to be in the ...
... ... OH (PRWEB) March 19, 2009 -- Female patients who require the removal ... extracted completely through the vagina, thanks to a new surgical procedure developed ... , , ,Dr. Jihad Kaouk, Director of the Center for Laparoscopic and ...
Cached Medicine News:Health News:Gleevec Prevents Return of Intestinal Cancer, Study Confirms 2Health News:Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International 2Health News:Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International 3Health News:Frost & Sullivan Recognizes GE Healthcare for Strategic Leadership in Acquiring Dynamic Imaging to Grow Its Imaging Informatics Business 2Health News:Frost & Sullivan Recognizes GE Healthcare for Strategic Leadership in Acquiring Dynamic Imaging to Grow Its Imaging Informatics Business 3Health News:Frost & Sullivan Recognizes GE Healthcare for Strategic Leadership in Acquiring Dynamic Imaging to Grow Its Imaging Informatics Business 4Health News:Frost & Sullivan Recognizes GE Healthcare for Strategic Leadership in Acquiring Dynamic Imaging to Grow Its Imaging Informatics Business 5Health News:Dr. Barry Friedberg comments on David vs. Goliath: Who's Really in the Pursuit of Patient Safety & Satisfaction? 2Health News:Cleveland Clinic First To Perform Nephrectomy Completely Transvaginally 2Health News:Cleveland Clinic First To Perform Nephrectomy Completely Transvaginally 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: